Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA

被引:6
|
作者
Sinari, Shripad [1 ]
Koska, Juraj [2 ,9 ]
Hu, Yueming [3 ]
Furtado, Jeremy [4 ]
Jensen, Majken K. [4 ,5 ]
Budoff, Matthew J. [6 ]
Nedelkov, Dobrin [3 ]
McClelland, Robyn L. [7 ]
Billheimer, Dean [1 ]
Reaven, Peter [8 ]
机构
[1] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA
[2] Phoenix VA Hlth Care Syst, Phoenix, AZ USA
[3] Isoformix Inc, Phoenix, AZ USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA
[5] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark
[6] Harbor Univ Calif Los Angeles UCLA, Lundquist Inst, Torrance, CA USA
[7] Univ Washington, Dept Biostat, Seattle, WA USA
[8] Arizona State Univ, Coll Hlth Solut, Phoenix, AZ USA
[9] Phoenix VA Hlth Care Syst, 650 E Indian Sch Rd CS111E, Phoenix, AZ 85012 USA
关键词
apolipoprotein; cardiovascular disease; lipids; risk; APOLIPOPROTEIN-C-III; LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; SIALIC-ACID; ASSOCIATION; INHIBITION; ATHEROSCLEROSIS; POLYMORPHISM; CHOLESTEROL; EXPRESSION;
D O I
10.1161/ATVBAHA.123.319035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background:Apo CIII (apolipoprotein CIII) is an important regulator of triglyceride metabolism and was associated with cardiovascular risk in several cohorts. It is present in 4 major proteoforms, a native peptide (CIII0a), and glycosylated proteoforms with zero (CIII0b), 1 (CIII1, most abundant), or 2 (CIII2) sialic acids, which may differentially modify lipoprotein metabolism. We studied the relationships of these proteoforms with plasma lipids and cardiovascular risk. Methods:Apo CIII proteoforms were measured by mass spectrometry immunoassay in baseline plasma samples of 5791 participants of Multi-Ethnic Study of Atherosclerosis, an observational community-based cohort. Standard plasma lipids were collected for up to 16 years and cardiovascular events (myocardial infarction, resuscitated cardiac arrest, or stroke) were adjudicated for up to 17 years. Results:Apo CIII proteoform composition differed by age, sex, race and ethnicity, body mass index, and fasting glucose. Notably, CIII1 was lower in older participants, men and Black and Chinese (versus White) participants, and higher in obesity and diabetes. In contrast, CIII2 was higher in older participants, men, Black, and Chinese persons, and lower in Hispanic individuals and obesity. Higher CIII2 to CIII1 ratio (CIII2/III1) was associated with lower triglycerides and higher HDL (high-density lipoprotein) in cross-sectional and longitudinal models, independently of clinical and demographic risk factors and total apo CIII. The associations of CIII0a/III1 and CIII0b/III1 with plasma lipids were weaker and varied through cross-sectional and longitudinal analyses. Total apo CIII and CIII2/III1 were positively associated with cardiovascular disease risk (n=669 events, hazard ratios, 1.14 [95% CI, 1.04-1.25] and 1.21 [1.11-1.31], respectively); however, the associations were attenuated after adjustment for clinical and demographic characteristics (1.07 [0.98-1.16]; 1.07 [0.97-1.17]). In contrast, CIII0b/III1 was inversely associated with cardiovascular disease risk even after full adjustment including plasma lipids (0.86 [0.79-0.93]). Conclusions:Our data indicate differences in clinical and demographic relationships of apo CIII proteoforms, and highlight the importance of apo CIII proteoform composition in predicting future lipid patterns and cardiovascular disease risk.
引用
收藏
页码:1560 / 1571
页数:12
相关论文
共 50 条
  • [21] Endurance exercise, plasma oxidation and cardiovascular risk
    Sharman, JE
    Geraghty, DP
    Shing, CM
    Fraser, DI
    Coombes, JS
    ACTA CARDIOLOGICA, 2004, 59 (06) : 636 - 642
  • [22] Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis
    Seah, Jowy Yi Hoong
    Chew, Wee Siong
    Torta, Federico
    Khoo, Chin Meng
    Wenk, Markus R.
    Herr, Deron R.
    Choi, Hyungwon
    Tai, E. Shyong
    van Dam, Rob M.
    METABOLOMICS, 2020, 16 (09)
  • [23] New views on the relationship of plasma lipids to cardiovascular disease
    Tracy, RP
    Tracy, PB
    CIRCULATION, 1997, 95 (06) : 1347 - 1348
  • [24] Inflammation, lipids and cardiovascular risk: The quest for improving risk stratification and prognosis in ischemic heart disease
    Romiti, Giulio Francesco
    Buoninfante, Giovanni
    Basili, Stefania
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2025, 55 (04)
  • [25] Plasma legumain in familial hypercholesterolemia: associations with statin use and cardiovascular risk markers
    Gregersen, Ida
    Narverud, Ingunn
    Christensen, Jacob Juel
    Hovland, Anders
    Oyri, Linn K. L.
    Ueland, Thor
    Retterstol, Kjetil
    Bogsrud, Martin P.
    Aukrust, Pal
    Halvorsen, Bente
    Holven, Kirsten B.
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2024, 84 (01) : 24 - 29
  • [26] Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
    S. van Dieren
    U. Nöthlings
    Y. T. van der Schouw
    A. M. W. Spijkerman
    G. E. H. M. Rutten
    D. L. van der A
    D. Sluik
    C. Weikert
    H. G. Joost
    H. Boeing
    J. W. J. Beulens
    Diabetologia, 2011, 54 : 73 - 77
  • [27] Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus
    van Dieren, S.
    Noethlings, U.
    van der Schouw, Y. T.
    Spijkerman, A. M. W.
    Rutten, G. E. H. M.
    van der A, D. L.
    Sluik, D.
    Weikert, C.
    Joost, H. G.
    Boeing, H.
    Beulens, J. W. J.
    DIABETOLOGIA, 2011, 54 (01) : 73 - 77
  • [28] Trajectories of Lipids Profile and Incident Cardiovascular Disease Risk: A Longitudinal Cohort Study
    Dayimu, Alimu
    Wang, Chunxia
    Li, Jiangbing
    Fan, Bingbing
    Ji, Xiaokang
    Zhang, Tao
    Xue, Fuzhong
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (21):
  • [29] Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study
    Nazarzadeh, Milad
    Pinho-Gomes, Ana-Catarina
    Bidel, Zeinab
    Dehghan, Abbas
    Canoy, Dexter
    Hassaine, Abdelaali
    Solares, Jose Roberto Ayala
    Salimi-Khorshidi, Gholamreza
    Smith, George Davey
    Otto, Catherine M.
    Rahimi, Kazem
    EUROPEAN HEART JOURNAL, 2020, 41 (40) : 3913 - +
  • [30] Plasma glucosylceramides and cardiovascular risk in incident hemodialysis patients
    Mitsnefes, Mark M.
    Fitzpatrick, Jessica
    Sozio, Stephen M.
    Jaar, Bernard G.
    Estrella, Michelle M.
    Monroy-Trujillo, Jose M.
    Zhang, Wujuan
    Setchell, Kenneth
    Parekh, Rulan S.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (06) : 1513 - 1522